Connect with us

Technology

Seegene’s CURECA(TM) Emerges as a Potential Game Changer in End-to-End PCR Automation

Published

1 year ago

on

Seegene previews a concept video of CURECATM at ESCMID Global 2025, ahead of its anticipated debut in JulyWith a fully modular design, CURECATM introduces a bold vision for automating pre-treatment across diverse PCR specimen typesDeveloped for future integration into unattended workflows and adaptable laboratory settings

SEOUL, South Korea, May 2, 2025 /PRNewswire/ — Seegene Inc., a global leader in molecular diagnostics (MDx) solutions, has attracted strong interest after the company presented a conceptual video of its CURECATM at the European Society of Clinical Microbiology and Infectious Diseases (ESCMID Global 2025) in Vienna, Austria. 

Industry professionals recognized CURECATM as a promising advancement in automating the entire PCR diagnostic workflow — from primary sample handling to result analysis. In response to the interest received, Seegene provided additional opportunities to showcase the solution at the ESCMID Global 2025.

More than 2,300 attendees — including dignitaries from Italy, Spain, Germany, France, and Canada — visited Seegene’s booth to view the conceptual video introducing the CURECATM. “It was evident that the Seegene booth attracted considerable attention at ESCMID,” said one professional from academia.

Experts Recognize CURECATM as a Game Changer in Molecular Testing Automation

The CURECATM is designed to automate the entire PCR diagnostic process. It can handle various specimen types required in the pre-treatment stage in MDx – such as stool, urine, blood, and sputum—as well as perform the complete PCR testing workflow following sample loading. 

The following are select comments from industry professionals who previewed Seegene’s CURECATM at ESCMID Global 2025:

“I hold high expectations for the fully automated PCR molecular diagnostics, as CURECATM not only eliminates human error inherent in manual processes but also enables efficient testing without time or workforce constraints.”

“We often encounter specimen types that require careful and time-consuming manual pre-processing. A system that can automate this step could represent a true paradigm shift. This level of automation is transformative – a real game changer – and unlike any existing solution. I eagerly await its launch.”

“If paired with our in-house diagnostic tool kits, CURECATM could offer a complete synergy. I hope CURECATM will be accessible to small and mid-sized facilities.”

“I’m planning to attend ADLM 2025 in Chicago in July to see the actual device and explore potential collaborations.”

Customizable Pre-Treatment System Offers Versatility for Future Laboratory Automation

The first component of CURECATM is the Customizable Pre-treatment System (CPS). The CPS is designed to automate the loading of primary sample tubes and operate pre-treatment processing.

“The CPS is a modular, automated system intended to streamline pre-treatment processing across diverse diagnostic fields including molecular diagnostics such as PCR, as well as clinical chemistry and immunology assays,” said Young-Seag Baeg, Head of Strategy and Planning at Seegene.

Numerous healthcare (or laboratory) professionals at ESCMID Global 2025 noted that the conceptual video of CURECATM showcased the potential of fully automated diagnostic laboratories capable of managing complex workflows associated with pre-treatment. In particular, there was consensus among participants that the CPS, which automates specimen preprocessing, is positioned to bring a significant advancement in in vitro diagnostics as it addresses limitations associated with existing manual procedures that are dependent on trained laboratory professionals.

“The turnaround time (TAT) is expected to improve with CURECATM as the integrated software is capable of adjusting workflows based on reporting deadlines,” said a director of a laboratory in Spain. “In particular, for sexually transmitted infections (STIs), the CPS will markedly enhance daily laboratory operations. The processing of specimens for STIs involves manual handling of multiple sample tubes, which contributes to operator fatigue. The adoption of the CPS has the potential to be transformational in streamlining routine operations.” 

Modular and Configurable Solution Design for Tailored Diagnostics

Following specimen preprocessing, molecular diagnostics typically involve nucleic acid extraction, PCR setup and amplification, and analysis of results. For specimens that do not need preprocessing, Seegene offers the Primary Sample Aliquot System (PAS) as an alternative to the CPS. PAS is designed to allow direct loading and dispensing of primary samples, helping to simplify the workflow. Seegene is pursuing the integration of PAS with a fully automated PCR process through a modular solution concept called CEFA (Customizable & Expandable Full Automation), intended to support diverse laboratory needs with greater flexibility.

Seegene aims to leverage the modular architecture of CURECATM to support a wide range of diagnostic applications. “CURECATM can be deployed as a comprehensive system or as individual modules—CPS, PAS, and CEFA—configured independently or in combination to accommodate diverse operational needs,” said Baeg.

Optimizing Lab Workflows Through Space-Saving Design

Another key advantage of the CURECATM’s modular architecture is that it is designed to adapt to different laboratory spaces and layouts. Its flexible design is intended to allow labs to configure the system according to their specific needs, which Seegene sees as essential for enhancing operational efficiency.

Laboratory professionals at ESCMID 2025 shared the following perspectives:

“The ability to configure a system to meet specific spatial and operational needs of individual laboratories represents a novel and highly compelling approach.”

“We expect such flexibility will make it possible to implement workflows that deliver high-quality results with minimal reliance on standardized laboratory configurations and staffing resources.”

“The enthusiastic global response to our concept video and vision for CURECATM demonstrate the strong demand for next-generation diagnostic solutions,” said Jong-Yoon Chun, CEO of Seegene. “We believe CURECATM has the potential to catalyze meaningful change in the global PCR diagnostics landscape.”

Please Note:

The comments included in this press release are based on actual interviews and on-site discussions. However, in accordance with requests to protect the privacy of the individuals interviewed, all names have been pseudonimized.

About Seegene

Seegene has more than 20 years of dedicated experience in R&D, manufacturing, and business related to syndromic real-time PCR technologies. This expertise was particularly highlighted during the COVID-19 pandemic when Seegene provided over 340 million COVID-19 tests to more than 100 countries worldwide. The core feature of Seegene’s syndromic real-time PCR technology is the ability to simultaneously test for 14 pathogens that cause similar signs and symptoms in a single tube with quantitative information.

Visit: Seegene.com and follow linkedin.com/company/seegene-inc

Technology-sharing Initiative

The technology-sharing initiative aims to globally share Seegene’s advanced diagnostic and data analysis technologies, including syndromic real-time PCR and an automated product development system (SGDDS), with a leading company partnered in each country. Partnering companies will collaborate with local scientists and experts to develop diagnostic tests tailored to the needs of their communities and fields, spanning a wide range of human and non-human diseases. The initiative’s ultimate vision is to create “a world free from diseases”—a future where people no longer suffer from infectious diseases and cancer, and where animals and plants thrive without illness.

 

 

Photo – https://mma.prnewswire.com/media/2677171/PHOTO_1.jpg

Photo – https://mma.prnewswire.com/media/2677172/Photo_2_1__Seegene_presented_a_concept_video_of_its_CURECA__system_at_ESCMID_2025__held_April_11_15.jpg

Photo – https://mma.prnewswire.com/media/2677173/Photo_2_2__Seegene_s_CURECA__concept_video_drew_interest_from_attendees_during_ESCMID_2025__held_Apr.jpg

Logo – https://mma.prnewswire.com/media/1357790/5295869/Seegene_logo_Logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/seegenes-curecatm-emerges-as-a-potential-game-changer-in-end-to-end-pcr-automation-302444934.html

Related Topics:
Continue Reading

Technology

BCE reports results of Series S and T preferred share conversions

Published

1 hour ago

on

October 19, 2026

By

MONTRÉAL, Oct. 19, 2026 /CNW/ — BCE Inc. (TSX: BCE) (NYSE: BCE) today announced that 400 of its 4,798,333 fixed-rate Cumulative Redeemable First Preferred Shares, Series T (“Series T Preferred Shares”) have been tendered for conversion on November 2, 2026, on a one-for-one basis, into floating-rate Cumulative Redeemable First Preferred Shares, Series S (“Series S Preferred Shares”). In addition, 676,765 of its 1,866,877 Series S Preferred Shares have been tendered for conversion on November 2, 2026, on a one-for-one basis, into Series T Preferred Shares. Consequently, on November 2, 2026, BCE will have 5,474,698 Series T Preferred Shares and 1,190,512 Series S Preferred Shares issued and outstanding. The Series T Preferred Shares and the Series S Preferred Shares will continue to be listed on the Toronto Stock Exchange under the symbols BCE.PR.T and BCE.PR.S, respectively.

The Series T Preferred Shares will pay on a quarterly basis, for the five-year period beginning on November 2, 2026, as and when declared by the Board of Directors of BCE, a fixed cash dividend based on an annual fixed dividend rate of 5.523%.

The Series S Preferred Shares will continue to pay a monthly floating adjustable cash dividend for the five-year period beginning on November 2, 2026, as and when declared by the Board of Directors of BCE. The monthly floating adjustable dividend for any particular month will continue to be calculated based on the prime rate for such month and using the Designated Percentage for such month representing the sum of an adjustment factor (based on the market price of the Series S Preferred Shares in the preceding month) and the Designated Percentage for the preceding month.

About BCE
BCE is Canada’s largest communications company1, leading the way in advanced fibre and wireless networks, enterprise services and digital media. By delivering next-generation technology that leverages cloud-based and AI-driven solutions, we’re keeping customers connected, informed and entertained while enabling businesses to compete on the world stage. To learn more, please visit Bell.ca or BCE.ca.

1 Based on total revenue and total combined customer connections.

Media inquiries:
Ellen Murphy
media@bell.ca

Investor inquiries:
Krishna Somers
krishna.somers@bell.ca

View original content:https://www.prnewswire.com/news-releases/bce-reports-results-of-series-s-and-t-preferred-share-conversions-302913268.html

SOURCE BCE Inc.

Continue Reading

Technology

3M announces collaboration with GSEO to advance Expanded Beam Optical manufacturing and development

Published

2 hours ago

on

October 19, 2026

By

ST. PAUL, Minn., Oct. 19, 2026 /PRNewswire/ — 3M (NYSE: MMM) today announced a collaboration with Genius Electronic Optical Co., Ltd. (GSEO, Taiwan: 3406), an optical technology company, to advance technology development and manufacturing for 3M’s Expanded Beam Optical (EBO) solutions. In support of these efforts, 3M expects to make a strategic investment to acquire approximately 4.7% of GSEO’s common shares as part of the company’s private placement of newly issued shares, subject to customary closing conditions.

The collaboration brings together 3M’s EBO technology leadership, optical interconnect expertise, materials science, manufacturing scale and customer relationships with GSEO’s precision optics manufacturing capabilities and production scale. Together, the companies aim to support EBO commercialization and long-term capacity expansion to meet growing demand from hyperscale data centers and other advanced connectivity applications.

“3M is investing in capabilities and partnerships that can accelerate innovation for our customers,” said William Brown, 3M Chairman and CEO. “By selecting GSEO as a manufacturing partner and investing in the company, we are strengthening the path to scale next-generation optical connectivity solutions for high-performance data center infrastructure.”

GSEO’s existing precision optics manufacturing capabilities and technical development experience are expected to support manufacturing readiness for 3M’s EBO ferrules, co-packaged optics solutions and related optical interconnect applications. The collaboration is part of 3M’s broader EBO ecosystem strategy, which includes continued work with customers and partners across the optical interconnect market.

“GSEO is pleased to expand its relationship with 3M as we work together to advance optical interconnect solutions for next-generation data center infrastructure,” said Micro Kuo, GSEO CEO and President. “This collaboration brings together complementary technology and manufacturing strengths to support continued innovation and help meet the performance demands of high-growth connectivity markets.”

3M expects the strategic investment to close in the fourth quarter of 2026, subject to customary closing conditions.

Forward-Looking Statements
Certain statements in this release are considered “forward-looking statements” under the federal securities laws, including the Private Securities Litigation Reform Act of 1995, as amended, and are intended to enjoy the protection of those laws. Forward-looking statements may appear throughout this release and are typically identified by the words “aim,” “anticipate,” “believe,” “can,” “continue,” “could,” “estimate,” “evaluate,” “expect,” “forecast,” “future,” “goal,” “guidance,” “impact,” “initial,” “intend,” “likely,” “may,” “outlook,” “plan,” “possible,” “potential,” “predict,” “probable,” “project,” “seek,” “should,” “strategy,” “target,” “will,” “would,” and other words that are similar to, or have the opposite meanings of, those words. Forward-looking statements speak only as of the date they are made, 3M assumes no duty to update those statements, and readers are cautioned not to place undue reliance on any of those statements. Forward-looking statements are based on certain assumptions and expectations of future events and trends that are subject to risks and uncertainties, including those described in Part I, Item 1A, “Risk Factors” of 3M’s Form 10-K for the year ended December 31, 2025.

About 3M
3M (NYSE: MMM) is focused on transforming industries around the world by applying science and creating innovative, customer-focused solutions. Our multi-disciplinary team is working to solve tough customer problems by leveraging diverse technology platforms, differentiated capabilities, global footprint, and operational excellence. Discover how 3M is shaping the future at 3M.com/news.

Contacts
3M
Investor Contact:
Diane Farrow, 612-202-2449
Media Contact:
3MNews@mmm.com 

View original content to download multimedia:https://www.prnewswire.com/news-releases/3m-announces-collaboration-with-gseo-to-advance-expanded-beam-optical-manufacturing-and-development-302913170.html

SOURCE 3M Company

Continue Reading

Technology

Scott Vicknair Personal Injury Lawyers Announces Second Annual Operation Fur-Ever Home Pet Adoption Event at Lafreniere Park

Published

2 hours ago

on

October 19, 2026

By

NEW ORLEANS, Oct. 19, 2026 /PRNewswire/ — Scott Vicknair Personal Injury Lawyers is excited to announce the return of its second annual Operation Fur-Ever Home, a free community pet adoption event taking place on Saturday, November 14, 2026, from 9:00 a.m. to 11:00 a.m. at Lafreniere Park in Metairie, Louisiana.

The free, family-friendly event will give attendees the opportunity to meet adoptable pets from local animal shelters, learn about responsible pet ownership, and potentially welcome a new furry companion into their homes. Those who preregister for the event will also be entered for a chance to win a Soundcore speaker and a free pet adoption.

“Last year’s event was everything we hoped it would be, and we are incredibly excited to bring Operation Fur-Ever Home back for a second year,” said David Vicknair, founding partner of Scott Vicknair Personal Injury Lawyers. “There is something special about watching a family meet a pet that could become part of their lives for years to come. We wanted to create another opportunity to make those connections while supporting the organizations that work tirelessly to care for animals in our community.”

Building on the success of the first event, this year’s event continues the firm’s commitment to supporting local animal shelters and creating meaningful opportunities for families throughout Southeast Louisiana.

“Giving back to our community has always been an important part of who we are as a firm,” said Vicknair. “Whether we are helping students prepare for school, recognizing deserving teachers, or supporting local animal shelters, our goal is to make a positive difference in the communities we serve.”

Operation Fur-Ever Home is free and open to the public. Families, animal lovers, and anyone interested in adopting a pet are encouraged to attend and preregister.

About Scott Vicknair Personal Injury Lawyers

Scott Vicknair Personal Injury Lawyers is a New Orleans-based personal injury firm committed to providing exceptional legal representation while also investing in the communities it serves. Their experienced team of dedicated attorneys specializes in car accidents, personal injury, and wrongful death cases in New Orleans. With diverse personal and professional backgrounds, they craft legal strategies tailored to each client’s specific case and needs.

View original content:https://www.prnewswire.com/news-releases/scott-vicknair-personal-injury-lawyers-announces-second-annual-operation-fur-ever-home-pet-adoption-event-at-lafreniere-park-302913183.html

SOURCE Scott Vicknair Personal Injury Lawyers

Continue Reading

Trending